A UK biotech looks to upset the preclinical model for liver drug development, and now it's gearing up for the clinic
Liver disease is one of the hardest therapeutic areas to hit, and some researchers have pointed to a dearth of meaningful preclinical models during drug development. Now, a UK biotech has figured out a workaround for its own siRNA liver drugs, and it all starts with discarded human organs.
Ochre Bio announced the closing of a $9.6 million seed financing round, led by Khosla Ventures. Backed VC, Apollo Health Ventures, Selvedge, Hoton and Hermes Epitek also participated in the fundraising.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.